Media headlines about Corvus Pharmaceuticals (NASDAQ:CRVS) have been trending positive on Tuesday, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Corvus Pharmaceuticals earned a media sentiment score of 0.31 on Accern’s scale. Accern also gave media coverage about the company an impact score of 47.2836409303729 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Research Analysts Set Expectations for Corvus Pharmaceuticals, Inc.’s Q2 2017 Earnings (NASDAQ:CRVS) (americanbankingnews.com)
- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Issues Earnings Results, Beats Estimates By $0.03 EPS (americanbankingnews.com)
- Corvus Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update (finance.yahoo.com)
- Corvus Pharmaceuticals, Inc. (CRVS) Coverage Initiated at Wedbush (americanbankingnews.com)
- Contrasting Jaguar Animal Health (JAGX) and Corvus Pharmaceuticals (CRVS) (americanbankingnews.com)
Corvus Pharmaceuticals (NASDAQ:CRVS) opened at 12.17 on Tuesday. The stock’s 50 day moving average is $11.94 and its 200-day moving average is $12.94. Corvus Pharmaceuticals has a 1-year low of $8.27 and a 1-year high of $22.14. The firm’s market capitalization is $254.77 million.
Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings results on Thursday, August 3rd. The company reported ($0.73) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.03. Equities research analysts forecast that Corvus Pharmaceuticals will post ($3.14) EPS for the current year.
Several equities analysts have issued reports on CRVS shares. Cowen and Company reissued a “buy” rating on shares of Corvus Pharmaceuticals in a research note on Tuesday, May 2nd. Zacks Investment Research cut shares of Corvus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, May 23rd. Credit Suisse Group cut shares of Corvus Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $10.00 price objective on the stock. in a research note on Monday, May 1st. Finally, Wedbush assumed coverage on shares of Corvus Pharmaceuticals in a research note on Wednesday, August 2nd. They issued an “outperform” rating and a $26.00 price objective on the stock. Five analysts have rated the stock with a buy rating, Corvus Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $20.50.
COPYRIGHT VIOLATION WARNING: “Favorable News Coverage Somewhat Unlikely to Impact Corvus Pharmaceuticals (NASDAQ:CRVS) Share Price” was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.themarketsdaily.com/2017/08/08/favorable-news-coverage-somewhat-unlikely-to-impact-corvus-pharmaceuticals-nasdaqcrvs-share-price.html.
In other Corvus Pharmaceuticals news, insider Richard A. Md Miller purchased 25,000 shares of the stock in a transaction dated Tuesday, June 13th. The shares were bought at an average cost of $9.88 per share, with a total value of $247,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Holdings A/S Novo purchased 20,000 shares of the stock in a transaction dated Friday, June 23rd. The shares were acquired at an average cost of $10.95 per share, for a total transaction of $219,000.00. Following the completion of the acquisition, the insider now directly owns 3,244,046 shares of the company’s stock, valued at approximately $35,522,303.70. The disclosure for this purchase can be found here.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.
Receive News & Ratings for Corvus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.